Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Melanoma Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
Market Growth and Contributing Factors
The global market for metastatic melanoma therapeutics is poised for considerable growth, with projections showing an increase from $7.27 billion in 2023 to $8.23 billion in 2024, marking a compound annual growth rate (CAGR) of 13.2%. This surge is driven by several pivotal factors, including the revolutionary advent and approval of immunotherapies, targeted therapy innovations, and successful clinical trials, all buoying up the market during the historical period.
Further growth is projected as the market moves towards a valuation of $12.87 billion by 2028, climbing at a CAGR of 11.8%. Expansion of patient populations, increased R&D initiatives, accelerated regulatory approvals, and emerging economies entering the market are expected to fuel the market's upward trajectory. Professional efforts continue to enhance the potency and reach of metastatic melanoma therapeutics, with stakeholders exploring immunotherapy combinations and advancing precision medicine.
Rising Incidence of Melanoma and Biologic Demand
A key driver for market expansion is the increasing incidence of melanoma cases worldwide. With an estimated 97,610 new cases expected in the US alone in 2023 and a projected global increase of more than 50% in cutaneous melanoma cases by 2040, the demand for metastatic melanoma therapeutics is likely to escalate.
The enlarging demand for biologics, high-efficacy therapeutic products, is anticipated to spur growth in the market further. These products offer patient-tailored, immunotherapy-based treatment modalities that have significantly improved outcomes and are associated with fewer side effects compared to traditional regimens.
Product Innovations and Strategic Collaborations
Innovation remains at the forefront of the metastatic melanoma therapeutics market's rise, with companies applying advanced technologies to cement their positions. Recent FDA approval of novel therapies such as KIMMTRAK underscores the trend towards innovative product offerings with demonstrated survival benefits.
Collaborations are also shaping the market landscape, as leading companies join forces to evaluate advanced treatment options for metastatic cutaneous melanoma. These partnerships focus on enhancing treatment efficacy and expanding the boundaries of existing therapeutic modalities.
Geographic Market Overview and Treatment Types
North America leads the metastatic melanoma therapeutics market, with significant regional contributions from Asia-Pacific, Western Europe, and other global regions. The market encompasses a variety of treatment modalities including chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgery, addressing different cancer stages and serving diverse healthcare settings.
The global market for metastatic melanoma therapeutics continues to evolve, propelled by scientific advancements, strategic business partnerships, and an unwavering commitment to improving patient outcomes. With a strong pipeline of products and a robust network of healthcare providers, the market is attuned to meet the growing needs arising from the rising prevalence of melanoma worldwide.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value (USD) in 2024 | $8.23 Billion |
| Forecasted Market Value (USD) by 2028 | $12.87 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- AbbVie Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- Daiichi Sankyo Company Ltd.
- Eisai Co. Ltd.
- Incyte Corporation
- Exelixis Inc.
- BeiGene Ltd
- Immunocore Holdings plc
- Genentech Inc.
- Iovance Biotherapeutics Inc.
- Nektar Therapeutics
- Adaptimmune Therapeutics plc
- AIVITA Biomedical Inc.
- Idera Pharmaceuticals Inc.
- Evaxion Biotech A/S
- AB Science
- AgonOX Inc.
- InxMed Co. Ltd.
- NewLink Genetics Corporation
- Vical Inc.
For more information about this report visit https://www.researchandmarkets.com/r/ykubqb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
